The significance of new somatostatin analogs as therapeutic agents.
The effects of somatostatin, or somatotropin release-inhibiting factor (SRIF), and SRIF analogs in human diseases have been widely investigated to potentially expand the therapeutic applications of commercially available and newly designed compounds belonging to this class of agents. Several preclinical studies and clinical trials have demonstrated the antiproliferative and antisecretory effects of SRIF and its analogs. This review discusses results from studies investigating the secretory activity and cell viability of SRIF analogs, and the potential of new therapeutic applications of these drugs in endocrine diseases and, in particular, as a treatment for endocrine neoplasia.
Department of Biomedical Sciences and Advanced Therapies, Section of Endocrinology, University of Ferrara, 44100 Ferrara, Italy.
Maria Chiara
MC
Zatelli
Ettore
E
degli Uberti
D000818:Animals; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D004701:Endocrine Gland Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D004700:Endocrine System Diseases / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D017481:Receptors, Somatostatin / Q000187:drug effects / Q000378:metabolism; D013004:Somatostatin / Q000031:analogs & derivatives*
D017481:Receptors, Somatostatin; D013004:Somatostatin